To the full analysis
IRadimed stock: growth
IRMDIRadimed reported $83.81M in revenue for fiscal 2025, up 14.4% on the prior year, up 21.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
20.2%
per year from 2012 to 2025, per share 18.3%
Earnings (Annual rate)
27.4%
per year from 2012 to 2025, per share 25.5%
Free cash flow (Annual rate)
21.6%
per year from 2012 to 2025, per share 19.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2012 | |
|---|---|---|---|
| Revenue | 21.5% | 10.2% | 20.2% |
| Revenue per share | 20.3% | 8.7% | 18.3% |
| Earnings | 75.0% | 11.6% | 27.4% |
| Earnings per share | 74.3% | 10.0% | 25.5% |
| Free cash flow | 27.1% | 8.9% | 21.6% |
| Free cash flow per share | 25.9% | 7.3% | 19.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2012 | $7.69M | $966.09K | $1.35M |
| 2013 | $11.34M | $1.94M | $1.28M |
| 2014 | $15.65M | $2.05M | $1.98M |
| 2015 | $31.59M | $7.53M | $7.33M |
| 2016 | $32.5M | $7.21M | $7.88M |
| 2017 | $23.08M | $499.76K | $2.59M |
| 2018 | $30.44M | $6.3M | $7.11M |
| 2019 | $38.52M | $9.63M | $9.75M |
| 2020 | $31.72M | $1.37M | $5.18M |
| 2021 | $41.81M | $9.33M | $10.52M |
| 2022 | $53.3M | $12.83M | $8.17M |
| 2023 | $65.56M | $17.19M | $5.46M |
| 2024 | $73.24M | $19.23M | $17.62M |
| 2025 | $83.81M | $22.48M | $17.18M |
Revenue by region
Where IRadimed Corporation generates its revenue.
- United States84%
- International16%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| United States | $52.53M | $60.61M | $70.56M | 84.2% |
| International | $13.04M | $12.64M | $13.26M | 15.8% |
| Total revenue | $65.56M | $73.24M | $83.81M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Fairly valued since 12 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.